Cantor Fitzgerald Upgrades Adverum Biotechnologies to Overweight, Raises Price Target to $21

Cantor Fitzgerald analyst Alethia Young upgrades Adverum Biotechnologies (NASDAQ:ADVM) from Neutral to Overweight and raises the price target from $8 to $21.

Benzinga · 02/10/2020 11:24

Cantor Fitzgerald analyst Alethia Young upgrades Adverum Biotechnologies (NASDAQ:ADVM) from Neutral to Overweight and raises the price target from $8 to $21.